Immune persistence and safety survey (cohort survey) related to the first series of new corona recombinant protein vaccines and boosters
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000047920
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 579
Inclusion Criteria
Not provided
Exclusion Criteria
Those who are inappropriate as the subject of the survey determined by the principal investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety up to 4 weeks after initial or booster recipients of SARS-CoV-2 vaccine
- Secondary Outcome Measures
Name Time Method 1) Breakthrough infection rate up to 12 months after the final vaccination of SARS-CoV-2 vaccine. 2) Serious adverse events up to 12 months after the final vaccination of SARS-CoV-2 vaccine (regardless of causality). 3) Changes in COVID-19 antibody titer up to 12 months after the final vaccination of SARS-CoV-2 vaccine (some of the survey subjects). This may not be investigated if booster is given before 12 months.